

FOI 2645

18th September 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira - 32
- Adalimumab Biosimilar - 281
- Apremilast - 0
- Bimekizumab - 7
- Brodalumab - 6
- Certolizumab - 5
- Deucravacitinib - 0
- Dimethyl fumarate - 0
- Etanercept – Enbrel - 0
- Etanercept Biosimilar - 1
- Guselkumab - 64
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 7
- Ixekizumab - 107
- Risankizumab - 79
- Secukinumab - 33
- Tildrakizumab - 7
- Ustekinumab - 29
- Ustekinumab Biosimilar - 0
- Omalizumab - 41

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

- Adalimumab – Humira - 21
- Adalimumab Biosimilar - 49
- Bimekizumab - 0
- Certolizumab - 0
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 4
- Secukinumab - 6

- **Ustekinumab - 1**
- **Ustekinumab Biosimilar - 0**

Email: Foi.Team@Southerntrust.hscni.net